Back to Research Home
OSRHOSR Holdings Inc
Health Care · Biotechnology
$0.21+3.83%
As of 23 Oct 2026Mkt cap —
Stage 13
WAIT
Fundamentals
—/75
Technical
4.0/15
Independent
—/90
GCAE viewFundamental evidence is unavailable, so the engine cannot approve ownership
Price
- 1M
- −20.1%
- 3M
- −52.1%
- 6M
- −70.0%
- 1Y
- −66.9%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- —
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- —
- Operating margin
- —
- FCF margin
- —
- Current ratio
- 0.2x
Growth
- Revenue growth
- −17.7%Latest FY YoY
- Revenue CAGR
- −17.7%
- EPS CAGR
- —
- FCF CAGR
- —
Capital
- Share-count trend
- +71.0%3Y annualised
- Net debt
- $682,710
Annual trend
- CAGR 2024–2025
- −17.7%
- Latest · 2025
- $0B
- YoY
- −17.7%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
Fundamental evidence is unavailable, so the engine cannot approve ownership
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
More details & evidence
Production decision
- Stage 13
- WAIT
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded